Dianthus reveals preclinical data for its Phase II neuromuscular candidate
Clinical-stage biotech firm Dianthus Therapeutics has shared preclinical data of its investigational agent DNTH103 being tested in in vitro models of generalised myasthenia gravis (gMG) and chronic demyelinating polyneuropathy (CIDP).
Data from the blood of three patients with gMG showed that DNTH103 reached a 24.8% – 27.8% reduction from baseline in the fatigue index, which measures improvements in neurotransmission and muscle contraction. Myasthenia gravis is an autoimmune disorder that causes muscle weakness and fatigue due to disrupted communication between nerves and muscles.
A second dataset looked at the blood of patients with CIDP, showing that the highest dose of DNTH103 used restored levels of neuronal conduction velocity. CIDP is a neurological disorder characterised by progressive weakness and impaired sensory function in the legs and arms due to inflammation of the peripheral nerves.
The preclinical data, presented at the European Academy of Neurology (EAN) 2024 Congress in Helsinki, Finland, also showed that DNTH103 has the potential to be formulated as a patient-friendly, infrequent, subcutaneous (SC) self-administration.
DNTH103 is a fully human IgG4 monoclonal antibody that inhibits the active form of C1s, a protein involved in a pathway that promotes inflammation. This pathway, known as the classical complement system, typically functions to clear microbes and damaged cells but is also suggested to play a role in some autoimmune diseases.
This data supports Dianthus’s recently initiated Phase II study. The MaGic trial (NCT06282159) – which will enrol 60 gMG patients who are anti-acetylcholine receptor (AChR) antibody-positive – was initiated in February 2024. Patients will receive DNTH103 via SC injection every two weeks, with topline data expected in H2 2025.
July 3, 2024
